Early Triple Negative Breast Cancer clinical trials

Explore recruiting early triple negative breast cancer clinical trials.

Recruiting early triple negative breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Early Triple Negative Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A translational RANDOMIZED phase III study exploring the effect of the addition of capecitabine to Carboplatinum based chemotherapy in early “triple negative” breast cancer

Sweden, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

OPTPEMBRO : OPTimizing adjuvant prescription of PEMBROlizumab in patients with early-stage triple-negative breast cancer achieving pathologic complete response after standard neoadjuvant chemotherapy and pembrolizumab

France, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immuno-chemotherapy in patients with early triple-negative breast cancer (TNBC). An open-label randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK

France

Therapeutic exploratory (Phase II) EU CTIS Study details

ETNA: Adjuvant pembrolizumab and chemotherapy or surveillance in Early Triple Negative breAst cancer with high stromal tumor-infiltrating lymphocytes (TILs) score

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Early Triple Negative Breast Cancer trials by city

Early Triple Negative Breast Cancer in Toronto Early Triple Negative Breast Cancer in Vancouver Early Triple Negative Breast Cancer in Montreal Early Triple Negative Breast Cancer in Calgary Early Triple Negative Breast Cancer in Edmonton Early Triple Negative Breast Cancer in Ottawa Early Triple Negative Breast Cancer in Winnipeg Early Triple Negative Breast Cancer in Quebec City Early Triple Negative Breast Cancer in Hamilton Early Triple Negative Breast Cancer in Kitchener Early Triple Negative Breast Cancer in London Early Triple Negative Breast Cancer in Halifax Early Triple Negative Breast Cancer in New York Early Triple Negative Breast Cancer in Los Angeles Early Triple Negative Breast Cancer in Chicago Early Triple Negative Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease